A successful year
Xintela had a very eventful year with success regarding both projects and financing. The following presentation summarises the status of Xintela’s various activities and overall plans for the coming year. Through a directed issue of approximately MSEK 50 to the German orthopaedic company Bauerfeind AG, we achieved financial stability and a long-term owner with a […]
Xintela at partnering conferences
Xintela has worked intensively to connect the company with potential partners and international investors. Thomas Areschoug, Business Development Manager at Xintela, tells more about the conferences that the company attended during the autumn. Xintela participated in a number of partnering conferences during the autumn. First of all, why it is so important for Xintela to […]
Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers
Lund, Sweden, 8 January 2019 – Xintela announces today that the company’s international (PCT) patent application for quality-assured chondrocytes (cartilage cells), developed using the company’s integrin markers, was published on January 3, 2019 under publication number WO 2019/002547. The patent application relates to a further development of Xintela’s marker technology and quality test XACT and […]
Xintela and Catalent to co-develop brain cancer therapy
Lund, Sverige, 25 oktober 2018 – Xintela tillkännager idag att bolaget har tecknat ett samarbetsavtal med det amerikanska bolaget Redwood BioScience Inc, ett helägt dotterbolag till Catalent, Inc., världsledande inom antibody-drug conjugate (ADC) teknologi för cancerterapi. Parterna avser att gemensamt utveckla en ADC-baserad terapeutisk produkt med första inriktning på hjärntumören glioblastom, den vanligaste och mest […]
SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA
Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that Sven Kili extends his commitment to Xintela as Chief Medical Officer (CMO). Sven Kili, a board member and consultant to Xintela, extends his commitment to Xintela as CMO on a consultancy basis. Sven is a physician and specialist in orthopedics and, through leading […]
XINTELA TO SPIN OUT ONCOLOGY BUSINESS
Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that the company has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB. The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela’s owners and […]
Significant progress in Xintela
Significant progress in Xintela Xintela today announces an update on the company’s development programs. Xintela develops medical products based on its patented marker technology platform XINMARK® with a focus on cell therapy and oncology. All projects have made significant progress in terms of results, patents and financing solutions so far this year. Stem cell therapy […]
Xintela extends patent protection for degenerative joint diseases
Xintela today announced that the company’s international patent application directed to the prevention and treatment of degenerative joint diseases using stem cells, including osteoarthritis, has been published. The data on which the patent application is based are derived from the horse study conducted by Xintela in late 2016. It demonstrated that stem cells, selected using […]
Xintela signs Letter of Intent with CO.DON
Xintela AB (publ) announces today that the company has signed a Letter of Intent with the leading European cell therapy company CO.DON. The parties intend to co-develop a stem cell product for the treatment of osteoarthritis, based on Xintela’s stem cell technology. CO.DON will pay an exclusivity fee for a 6- month period, during which […]
Xintela receives MUMS-status for the treatment of osteoarthritis in horses
Lund, Sweden, 28th of June 2018 – Xintela announces today that the company has received MUMS-status (Minor Use Minor Species) in Europe for the treatment of degenerative joint disease, including osteoarthritis, in horses. MUMS-status is the veterinary equivalent of Orphan Drug in human medicine. The MUMS classification gives a significant reduction of documentation requirements prior […]
